Journal Article

Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection

Kanzaki, Go, Tsuboi, Nobuo, Haruhara, Kotaro

2023

Overview

Chronic kidney disease (CKD) is one of the strongest risk factors for hypertension, and hypertension can exacerbate the progression of CKD. Thus, the management of CKD and antihypertensive therapy are inextricably linked. Research over the past decades has shown that the human kidney is more diverse than initially thought. Subjects with low nephron endowment are at increased risk of developing CKD and hypertension, which is consistent with the theory of the developmental origins of health and disease. Combined with other lifetime risks of CKD, hypertension may lead to a vicious cycle consisting of podocyte injury, glomerulosclerosis and further loss of nephrons. Of note, recent studies have shown that the number of nephrons correlates well with the number of podocytes, suggesting that these two components are intrinsically linked and may influence each other. Both nephrons and podocytes have no or very limited regenerative capacity and are destined to decrease throughout life. Therefore, one of the best strategies to slow the progression of CKD is to maintain the “numbers” of these essential components necessary to preserve renal function. To this end, both the achievement of an optimal blood pressure and a maximum reduction in urinary protein excretion are essential. Lifestyle modifications and antihypertensive drug therapy must be carefully individualized to address the potential diversity of the kidneys.

• Publisher: Nature Publishing Group,Springer Nature Singapore
• Subject: Antihypertensive Agents - therapeutic use / Antihypertensives / Humans / Hypertension / Kidney / Kidney diseases / Nephrons - metabolism / Pathogenesis / Podocytes / Renal Insufficiency, Chronic / Review / Salt